Penumbra, Inc. (PEN) is a publicly traded Healthcare sector company. As of July 5, 2026, PEN trades at $318.57 with a market cap of $12.53B and a P/E ratio of 72.73. PEN moved +0.68% today. Year to date, PEN is +1.37%; over the trailing twelve months it is +27.56%. Its 52-week range spans $221.26 to $362.41. Analyst consensus is neutral with an average price target of $361.40. Rallies surfaces PEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Penumbra Secures FDA Clearance for THUNDERBOLT with Modulated Aspiration for Stroke Treatment: Penumbra obtained FDA clearance for its THUNDERBOLT computer assisted vacuum thrombectomy platform, introducing modulated aspiration to address acute ischemic stroke. As the only CAVT device approved for stroke in the U.S., THUNDERBOLT combines the Penumbra ENGINE with RED series catheters to enable faster, more complete clot removal.
| Metric | Value |
|---|---|
| Price | $318.57 |
| Market Cap | $12.53B |
| P/E Ratio | 72.73 |
| EPS | $4.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $362.41 |
| 52-Week Low | $221.26 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.45B |
| Net Income | $171.05M |
| Gross Margin | 67.39% |
5 analysts cover PEN: 0 strong buy, 1 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $361.40.